EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern

Jiayu Xu, Yuexiu Zhang iD, Panke Qu, Mohamed M Shamseldin, Sung J Yoo iD, Jack Misny, Ilada Thongpan, Mahesh Kc iD, Jesse M Hall, John P Evans iD, Mostafa Eltobgy iD, Mijia Lu und 11 weitere

Proceedings of the National Academy of Sciences · 10.10.2023 · 120 (41)

DOI: 10.1073/pnas.2220403120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 05.10.2023. Verfasst von Jiayu Xu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210. Hauptthemen laut MEDLINE: Mumps, COVID-19, Measles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As SARS-CoV-2 variants of concern (VoCs) that evade immunity continue to emerge, next-generation adaptable COVID-19 vaccines which protect the respiratory tract and provide broader, more effective, and durable protection are urgently needed. Here, we have developed one such approach, a highly efficacious, intranasally delivered, trivalent measles-mumps-SARS-CoV-2 spike (S) protein (MMS) vaccine candidate that induces robust systemic and mucosal immunity with broad protection. This vaccine candidate is based on three components of the MMR vaccine, a measles virus Edmonston and the two mumps virus strains [Jeryl Lynn 1 (JL1) and JL2] that are known to provide safe, effective, and long-lasting protective immunity. The six proline-stabilized prefusion S protein (preS-6P) genes for ancestral SARS-CoV-2 WA1 and two important SARS-CoV-2 VoCs (Delta and Omicron BA.1) were each inserted into one of these three viruses which were then combined into a trivalent “MMS” candidate vaccine. Intranasal immunization of MMS in IFNAR1 −/− mice induced a strong SARS-CoV-2-specific serum IgG response, cross-variant neutralizing antibodies, mucosal IgA, and systemic and tissue-resident T cells. Immunization of golden Syrian hamsters with MMS vaccine induced similarly high levels of antibodies that efficiently neutralized SARS-CoV-2 VoCs and provided broad and complete protection against challenge with any of these VoCs. This MMS vaccine is an efficacious, broadly protective next-generation COVID-19 vaccine candidate, which is readily adaptable to new variants, built on a platform with a 50-y safety record that also protects against measles and mumps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MumpsCOVID-19MeaslesCricetinaeAnimalsHumansMiceSARS-CoV-2COVID-19 VaccinesMeasles-Mumps-Rubella VaccineAntibodies, ViralBroadly Neutralizing AntibodiesImmunoglobulin GMesocricetusAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

MMR vaccineSARS-CoV-2intranasal trivalent vaccine

Substanzen

COVID-19 VaccinesMeasles-Mumps-Rubella VaccineAntibodies, ViralBroadly Neutralizing AntibodiesImmunoglobulin GAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
  • Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.
  • Department of Microbiology and Immunology, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt.
  • Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
  • Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.
  • Infectious Disease Institute, The Ohio State University, Columbus, OH 43210.

ORCID-Profile: Yuexiu Zhang, Sung J Yoo, Mahesh Kc, John P Evans, Mostafa Eltobgy, Chengjin Ye, Luis Martinez-Sobrido, Amal O Amer, Prosper N Boyaka, Mark E Peeples, Shan-Lu Liu, Purnima Dubey, Jianrong Li

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • HHS | National Institutes of Health
  • HHS | NIH | National Cancer Institute

Zitieren

APA

Xu, J., Zhang, Y., Qu, P., Shamseldin, M. M., Yoo, S. J., Misny, J., Thongpan, I., Kc, M., Hall, J. M., Evans, J. P., Eltobgy, M., Lu, M., Ye, C., Chamblee, M., Liang, X., Martinez-Sobrido, L., Amer, A. O., Yount, J. S., Boyaka, P. N., …, & Li, J. (2023). A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern. Proceedings of the National Academy of Sciences, 120(41). https://doi.org/10.1073/pnas.2220403120

Vancouver

Xu J, Zhang Y, Qu P, Shamseldin MM, Yoo SJ, Misny J, et al. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern. Proceedings of the National Academy of Sciences. 2023;120(41). doi:10.1073/pnas.2220403120

BibTeX
@article{Xu2023,
  author = {Xu, Jiayu and Zhang, Yuexiu and Qu, Panke and Shamseldin, Mohamed M and Yoo, Sung J and Misny, Jack and Thongpan, Ilada and Kc, Mahesh and Hall, Jesse M and Evans, John P and Eltobgy, Mostafa and Lu, Mijia and Ye, Chengjin and Chamblee, Michelle and Liang, Xueya and Martinez-Sobrido, Luis and Amer, Amal O and Yount, Jacob S and Boyaka, Prosper N and Peeples, Mark E and Liu, Shan-Lu and Dubey, Purnima and Li, Jianrong},
  title = {A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {41},
  doi = {10.1073/pnas.2220403120}
}
Kostenlos starten →